Treatment with blood transfusions is safe and efficient for treating hospitalized autoimmune hemolytic anemia (AIHA) patients, a large observational study suggests. This conclusion held true even when using incompatible donors and even for the one-third of patients who developed severe anemia during hospitalization, according to the study.
News
T follicular helper cells, a subset of T-cells that help other immune cells produce antibodies, seem to play a role in the development of autoimmune hemolytic anemia (AIHA), a mouse study suggests. The study, “The Role of T Follicular Helper Cells and T Follicular Regulatory Cells in…
News
Nearly $200,000 Awarded to Cold Agglutinin Disease Foundation, Other Rare Disease Organizations
The Cold Agglutinin Disease Foundation is among 20 rare disease organizations receiving funding under Global Genes‘ 2020 RARE Patient Impact Grant Program. Now in its fifth year, the 2020 grant program is awarding funds totaling almost $200,000 to these organizations. The program provides funding for rare disease patient…
Patients with autoimmune hemolytic anemia (AIHA) who undergo spleen removal surgery have a higher risk of blood clots than patients who did not have the surgery, a recent study suggests. The study, titled “Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia,”…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A 58-year-old kidney transplant patient developed autoimmune hemolytic anemia (AIHA) three days after receiving an influenza vaccine, a case study reports. The case highlights the importance of educating patients to report any unusual symptoms after vaccination. The study, “Autoimmune Hemolytic Anemia in a Renal Transplant Patient Following…
The investigational therapy sutimlimab prevented hemolysis, significantly increased hemoglobin, and improved the quality of life in patients with cold agglutinin disease (CAD), according to data from a Phase 3 clinical trial. The results will be presented at the Annual Meeting of the American Society of Hematology in December, in…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
Cold agglutinin disease (CAD) patients have an increased risk of developing blood clots compared to the general population, a retrospective Danish study shows. The findings of the study, “Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease” were published recently in the journal Blood Advances. In…
Restricted blood flow, or ischemia, in the nose of a cold agglutinin disease (CAD) patient can be successfully treated using a combination that includes aspirin, heparin, nitroglycerin ointment, and hyperbaric oxygen therapy, a case report details. The report, “A case report of severe nasal…
Recent Posts
- Immunochemotherapy can help control CAD but it carries safety risks
- Oral therapy iptacopan eases anemia in CAD patients: Small trial
- When living with CAD, even a short trip can be a nightmare
- Real-world study confirms long-term safety of Enjaymo for CAD
- After months of fatigue, feeling better is what I want for Christmas
- Man’s case shows bacterial lung infection can ‘provoke’ clots, CAD
- Living with cold agglutinin disease involves cruel curveballs
- Gastric lymphoma found to be hidden cause of refractory CAD
- New CAD treatments, like reading progress, prove growth is possible
- ANX1502 proof-of-concept trial to wrap up next year, Annexon says